Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Poseida Therapeutics Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are spread across 4 distinct examiners and 4 distinct art units, indicating separate examination tracks throughout the active portfolio.
LIPPOLIS, ALEXANDRA ROSE is the busiest examiner and handles 1 pending action. Counsel should coordinate overall claim strategy while preparing responses that address the distinct examiner and art-unit contexts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| §103 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 47.2% | +63.6% |
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | — |
| 17273030 | ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE | DAHLE, CHUN WU | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1657 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | 1657 | §101§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 17273030 | ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE | DAHLE, CHUN WU | 1641 | §103 | Final Rejection | — | Pending | Mar 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPoseida Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Alexandra Rose Lippolis has the most, with 1 of Poseida Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
